Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Johnson and Johnson
Harvard Business School
McKinsey
Dow

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

MORPHABOND ER Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Morphabond Er patents expire, and when can generic versions of Morphabond Er launch?

Morphabond Er is a drug marketed by Daiichi Sankyo Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-two patent family members in ten countries.

The generic ingredient in MORPHABOND ER is morphine sulfate. There are twenty-three drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.

Drug patent expirations by year for MORPHABOND ER
Drug Prices for MORPHABOND ER

See drug prices for MORPHABOND ER

Recent Litigation for MORPHABOND ER

Identify potential future generic entrants

District Court Litigation
Case NameDate
INSPIRION DELIVERY SCIENCES, LLC v. TEVA PHARMACEUTICALS USA, INC.2019-04-19

See all MORPHABOND ER litigation

Pharmacology for MORPHABOND ER
Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Synonyms for MORPHABOND ER
(4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;sulfuric acid;pentahydrate
(5alpha,6alpha)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol, hydrogen sulfate (2:1)
1095-53-0
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6-diol sulfate (2:1)
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6-diol sulfate (2:1) pentahydrate
178935-96-1
4,5-alpha-Epoxy-17-methylmorphinan-3,5-alpha-diol sulfate hydrate (2:1:5)
57-27-2 (Parent)
6211-15-0
64-31-3
66591-53-5
7,8-Didehydro-4,5alpha-epoxy-17-methylmorphinan-3,6alpha-diol sulfate (2:1) (salt) pentahydrate
92004-19-8
Apomorphine impurity B (morphine sulfate), European Pharmacopoeia (EP) Reference Standard
Arymo ER
Astramor PH (TN)
Astramorph
Astramorph PF
Avinza
Avinza (TN)
CAS-6211-15-0
CHEBI:50731
CHEBI:7003
CHEMBL2096625
CHEMBL2103744
D00842
Depodur (TN)
Di(morphine) dihydrogen sulfate pentahydrate
DSSTox_CID_28840
DSSTox_GSID_48914
DSSTox_RID_83109
DTXSID1048914
DTXSID4023830
Duramorph
Duramorph PF
DY70C97N30
EINECS 200-582-8
Kadian (TN)
Kapanol
l-Morphine sulfate
Morphabond
Morphinan-3,6-alpha-diol, 7,8-didehydro-4, 5-alpha-epoxy-17-methyl-, sulfate
Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)-, sulfate (2:1) (salt)
Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-(5-alpha,6-alpha)-, sulfate (2:1) (salt), pentahdrate
Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl, (5alpha,6alpha)-, sulfate (2:1) (salt), pentahydrate
Morphinan-3,6alpha-diol, 7,8-didehydro-4,5alpha-epoxy-17-methyl-, sulfate (2:1) (salt)
Morphinan-3,6alpha-diol, 7,8-didehydro-4,5lpha-epoxy-17-methyl-, sulfate (2:1) (salt), pentahydrate
Morphine Extra-Forte
Morphine for system suitability, European Pharmacopoeia (EP) Reference Standard
Morphine Forte
Morphine H.P
Morphine hemi[sulfate pentahydrate]
Morphine Hemisulfate Pentahemihydrate
Morphine Hemisulphate Pentahemihydrate
Morphine sulfat, European Pharmacopoeia (EP) Reference Standard
MORPHINE SULFATE
Morphine Sulfate (anhydrous)
Morphine sulfate (USP)
Morphine sulfate [USP:JAN]
Morphine sulfate hydrate
Morphine sulfate hydrate (JP17)
Morphine sulfate pentahydrate
Morphine sulfate salt pentahydrate
Morphine sulfate salt pentahydrate, analytical standard
Morphine sulfate salt solution
Morphine sulfate salt solution, 1.0 mg/mL in methanol, drug standard
Morphine sulfate, United States Pharmacopeia (USP) Reference Standard
Morphine sulphate
Morphine sulphate (2:1)
Morphine sulphate pentahydrate
Morphine, hemisulfate
MS contin (TN)
MST-1 Continus
NCGC00247707-01
NIH 0001
NIH 10753
NSC 11441
Oramorph SR
SCHEMBL29316
Skenan
Tox21_112861
UNII-DY70C97N30
UNII-X3P646A2J0
X3P646A2J0

US Patents and Regulatory Information for MORPHABOND ER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-001 Oct 2, 2015 RX Yes No   See Pricing   See Pricing Y   See Pricing
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-004 Oct 2, 2015 RX Yes Yes   See Pricing   See Pricing Y   See Pricing
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-002 Oct 2, 2015 RX Yes No   See Pricing   See Pricing Y   See Pricing
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-004 Oct 2, 2015 RX Yes Yes   See Pricing   See Pricing Y   See Pricing
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-001 Oct 2, 2015 RX Yes No   See Pricing   See Pricing Y   See Pricing
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-002 Oct 2, 2015 RX Yes No   See Pricing   See Pricing Y   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for MORPHABOND ER
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 15 mg, 30 mg, 60 mg and 100 mg ➤ Subscribe   See Pricing

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Merck
Colorcon
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.